New CV Outcomes Trials Examine Linagliptin and Glimepiride Among Patients With High CVD Risk
Mar 3, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Amber Satz, PharmD Candidate, LECOM School of Pharmacy
The CAROLINA and CARMELINA Trials offer further information regarding the CV safety of linagliptin and glimepiride among patients with T2DM, high CVD risk, and decreased renal function.
Patients with diabetes carry an increased risk of cardiovascular disease. Since the development of diabetes drugs, there has been attention to the impact that medications can have on diabetes patients’ cardiovascular health. Two recent significant studies analyzed the CV effect of the DPP4 linagliptin in patients already at high cardio-renal and cardiovascular risk....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.